MICROCRYSTALLINE CELLULOSE: A BIOPOLYMER WITH DIVERSIFORM APPLICATIONS
Source abstract
Abstract
With characteristics, such as white color, tasteless, odorless, neutral, non-reactive, non-toxic, stable, biocompatible, and biodegradable, along with excellent compaction properties, high mechanical strength, and low density, microcrystalline cellulose (MCC) stands out as a top excipient for direct compression tablets. As the demand for renewable, eco-friendly, and non-fossil materials becomes increasingly imperative, this most abundant biopolymer on Earth is sought not only in the pharmaceutical industry, but also in the cosmetics, food, construction, and wastewater treatment sectors. This review paper highlights the importance of this substance by describing its various applications across the mentioned industrial sectors, with a focus on direct compression tablets as the most commonly used oral dosage form. Results from numerous experiments have demonstrated the benefits of MCC as a component in a variety of products, including direct compression tablets, coated spheres, topical preparations, ice cream, cocoa, fried beef patties, sausages, cement, foamed concrete, and adsorbents for heavy metals in wastewater treatment.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced Cellulose Research Studies · Polysaccharides Composition and Applications · Electrohydrodynamics and Fluid Dynamics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. "1 O. A. Battista and P. A. Smith, US Patent No: 2 978 446 (1961)
2. 2 O. A. Battista and P. A. Smith, US Patent No: 3 023 104 (1962).
3. 3 O. A. Battista and P. A. Smith, US Patent No: 3 141 875 (1964)
4. 4 M. El-Sakhawy and M. L. Hassan, Carbohyd. Polym., 67, 1 (2007), https://doi.org/10.1016/j.carbpol.2006.04.00910.1016/j.carbpol.2006.04.009 ↗
5. 5 J. Albers, K. Knop and P. Kleinebudde, Pharm. Ind., 68, 1420 (2006)
6. 6 M. C. Gohel and P. D. Jogani, J. Pharm. Pharmaceut. Sci., 8, 76 (2005)
7. 7 https://www.pharmaexcipients.com/list-mcc-products-manufacturers/ (accessed on 08.14.2023)
8. 8 https://www.usp.org/harmonization-standards/pdg/excipients/microcrystalline-cellulose (accessed on 07.07.2023)
9. 9 D. F. Steele, PhD Thesis, University of Bath, England, 2002
10. 10 R. Ek, G. Alderborn and C. Nystrom, Int. J. Pharm., 111, 43 (1994), https://doi.org/10.1016/0378-5173(94)90400-610.1016/0378-5173(94)90400-6 ↗
11. 11 S. Westermarck, A. M. Juppo, L. Kervinen and J. Yliruusi, Eur. J. Pharm. Biopharm., 48, 199 (1999), https://doi.org/10.1016/s0939-6411(99)00051-x10.1016/S0939-6411(99)00051-X ↗
12. 12 S. B. A. Hamid, Z. Z. Chowdhury and Z. Karim, BioResources, 9, 7403 (2014), https://doi.org/10.15376/biores.9.4.7403-742610.15376/biores.9.4.7403-7426 ↗
13. 13 V. B. Ghodake, R. A. Khare and S. T. Mhaske, Cellulose Chem. Technol., 57, 475 (2023), https://doi.org/10.35812/CelluloseChemTechnol.2023.57.4310.35812/CelluloseChemTechnol.2023.57.43 ↗
14. 14 G. O. Phillips and P. A. Williams (Eds.), "Handbook of Hydrocolloids", 2nd ed., CRC Press, 200910.1533/9781845695873 ↗
15. 15 https://eur-lex.europa.eu/eli/reg/2008/1333/2023-10-29 (accessed on February 26, 2024)
16. 16 R. D. Rahane and P. R. Rachh, J. Drug Deliv. Ther., 8, 50 (2018), https://doi.org/10.22270/jddt.v8i5.188810.22270/jddt.v8i5.1888 ↗
17. 17 USP29, 2006, http://www.pharmacopeia.cn/v29240/usp29nf24s0_c1151s87.html (accessed on 07.07.2023)
18. 18 N. Saigal, S. Baboota, A. Ahuja and J. Ali, J. Young Pharm., 1, 6 (2009), https://doi.org/10.4103/0975-1483.5186810.4103/0975-1483.51868 ↗
19. 19 K. M. Picker, Eur. J. Pharm. Biopharm., 48, 27 (1999), https://doi.org/10.1016/s0939-6411(99)00009-010.1016/S0939-6411(99)00009-0 ↗
20. 20 M. Jivraj, L. G. Martini and C. M. Thomson, Pharm. Sci. Technol. Today, 3, 58 (2000), https://doi.org/10.1016/S1461-5347(99)00237-010.1016/S1461-5347(99)00237-0 ↗
21. 21 R. C. Rowe, P. J. Sheskey and S. C. Owen (Eds.), "Handbook of Pharmaceutical Excipients", 5th ed., Pharmaceutical Press, 2006, p. 132
22. 22 A. H. Kibbe (Ed.), "Handbook of Pharmaceutical Excipients", 3rd ed., The American Pharmaceutical Association/Pharmaceutical Press, 2000
23. 23 J. Nsor-Atindana, M. Chen, D. H. Goff, F. Zhonga, H. R. Sharif et al., Carbohyd. Polym., 172, 159 (2017), https://doi.org/10.1016/j.carbpol.2017.04.02110.1016/j.carbpol.2017.04.021 ↗
24. 24 S. S. Z. Hindi, J. Nanosci. Nanotechnol., 4, 17 (2017), https://doi:10.12691/nnr-4-1-3
25. 25 V. Miljković, I. Gajić and L. Nikolić, Polymers (Basel), 13, 4115 (2021), https://doi:10.3390/polym1323411510.3390/polym13234115 ↗
26. 26 I. Valchev, N. Yavorov and D. Todorova, Cellulose Chem. Technol., 54, 259 (2020), https://doi.org/10.35812/CelluloseChemTechnol.2020.54.2710.35812/CelluloseChemTechnol.2020.54.27 ↗
27. 27 D. Trache, M. H. Hussin, C. T. H. Chuin, S. Sabar, M. R. Nurul Fazita et al., Int. J. Biol. Macromol., 93, 789 (2016), https://doi.org/10.1016/j.ijbiomac.2016.09.05610.1016/j.ijbiomac.2016.09.056 ↗
28. 28 N. Y. Abu-Thabit, A. A. Judeh, A. S. Hakeem, A. Ul-Hamid, Y. Umar et al., Int. J. Biol. Macromol., 155, 730 (2020), https://doi.org/10.1016/j.ijbiomac.2020.03.25510.1016/j.ijbiomac.2020.03.255 ↗
29. 29 R. L. D. Oliveira, H. D. S. Barud, R. M. N. D. Assuncao, C. D. S. Meireles, G. O. Carvalho et al., Int. J. Pharm., 111, 43 (1994)
30. 30 G. Thoorens, F. Krier, B. Leclercq, B. Carlin and B. Evrard, Int. J. Pharm., 473, 64 (2014), https://doi.org/10.1016/j.ijpharm.2014.06.05510.1016/j.ijpharm.2014.06.055 ↗
31. 31 S. Bredenberg, PhD Dissertation, Uppsala Universitet, Sweden, 2003
32. 32 S. W. Hoag, V. S. Dave and V. Moolchandani, in "Pharmaceutical Dosage Forms: Tablets, Volume 1: Unit Operations and Mechanical Properties", edited by L. L. Augsburger and S. W. Hoag, Informa Healthcare, 2008, pp. 555-630, https://doi.org/10.3109/978142002028110.3109/9781420020281 ↗
33. 33 M. Chatrath, PhD Thesis, University of Bath, United Kingdom, 1992
34. 34 M. Landin, R. Martinez-Pacheco, J. L. Gomez-Amoza, C. Souto, A. Concheiro et al., Int. J. Pharm., 103, 9 (1994), https://doi.org/10.1016/0378-5173(94)90198-810.1016/0378-5173(94)90198-8 ↗
35. 35 J. B. Schwartz and L. Lachman, in "Pharmaceutical Dosage Forms: Tablets Vol. 1", edited by J. F. Bandelin, Marcel Dekker Inc., 1990, p. 158
36. 36 E. Doelker, Drug Dev. Ind. Pharm., 19, 2399 (1993), https://doi.org/10.3109/0363904930904719610.3109/03639049309047196 ↗
37. 37 G. Shlieout, K. Arnold and G. Muller, AAPS PharmSciTech, 3, 45 (2002), https://doi.org/10.1208/pt03021110.1208/pt030211 ↗
38. 38 N. A. Armstrong and L. P. Palfrey, J. Pharm. Pharmacol., 41, 149 (1989), https://doi.org/10.1111/j.2042-7158.1989.tb06418.x10.1111/j.2042-7158.1989.tb06418.x ↗
39. 39 P. G. Karehill and C. Nystrom, Int. J. Pharm., 64, 27 (1990), https://doi.org/10.1016/0378-5173(90)90175-410.1016/0378-5173(90)90175-4 ↗
40. 40 G. K. Bolhuis and Z. T. Chowhan, in "Pharmaceutical Powder Compaction Technology", edited by G. Alderborn and C. Nystrom, Marcel Dekker Inc., 1996, pp. 419-50010.1201/b14207-15 ↗
41. 41 K. F. M. Pasqualoto, J. A. B. Funck, F. E. B. da Silva and C. D. P. Kratz, Acta Farm. Bonaerense, 24, 39 (2005)
42. 42 J. F. Bavitz and J. B. Schwartz, Drug Cosmetic Ind., 114, 44 (1974)
43. 43 D. K. Mehra, K. P. West and J. D. Wiggins, US Patent No: 4744987, 1987
44. 44 N. A. Armstrong, G. Roscheisen and M. R. A. K. Alaghbar, Manuf. Chem., 67, 25 (1996)
45. 45 P. M. Belda and J. B. Mielck, Eur. J. Pharm. Biopharm., 42, 325 (1996)
46. 46 C. F. Lerk, G. K. Bolhuis and A. H. de Boer, Pharm. Weekbl., 109, 945 (1974)
47. 47 J. I. Wells and J. R. Langridge, Int. J. Tech. Prod. Manuf., 2, 1 (1981)
48. 48 J. S. M. Garr and M. H. Rubinstein, Int. J. Pharm., 73, 75 (1991), https://doi.org/10.1016/0378-5173(91)90102-T10.1016/0378-5173(91)90102-T ↗
49. 49 G. E. Reier and R. F. Shangraw, J. Pharm. Sci., 55, 510 (1966), https://doi.org/10.1002/jps.260055051310.1002/jps.2600550513 ↗
50. 50 G. K. Bolhuis, C. F. Lerk and P. Broersme, Drug. Dev. Ind. Pharm., 6, 15 (1980), https://doi.org/10.3109/0363904800905192410.3109/03639048009051924 ↗
51. 51 D. Yasmin, R. Rahman and M. Akter, Int. Curr. Pharm. J., 2, 112 (2013), https://doi.org/10.3329/icpj.v2i6.1487110.3329/icpj.v2i6.14871 ↗
52. 52 B. N. Nalluri, D. Jyotheermayi, D. Anusha and K. M. Maheswari, J. Chem. Pharm. Res., 4, 4266 (2012)
53. 53 R. Mustarichie and D. Priambodo, Int. J. Appl. Pharm., 10, 98 (2018), https://doi.org/10.22159/ijap.2018v10i4.2679510.22159/ijap.2018v10i4.26795 ↗
54. 54 Y. Watanabe, K. Koizumi, Y. Zama, M. Kiriyama, Y. Matsumoto et al., Biol. Pharm. Bull., 18, 1308 (1995), https://doi.org/10.1248/bpb.18.130810.1248/bpb.18.1308 ↗
55. 55 P. Sherman, J. Food. Sci., 34, 458 (1969), https://doi.org/10.1111/j.1365-2621.1969.tb12804.x10.1111/j.1365-2621.1969.tb12804.x ↗
56. 56 Y. Bi, H. Sunada, Y. Yonezawa, K. Danjo, A. Otsuka et al., Chem. Pharm. Bull., 44, 2121 (1996), https://doi.org/10.1248/cpb.44.212110.1248/cpb.44.2121 ↗
57. 57 T. Ishikawa, B. Mukai, S. Shiraishi, N. Utoguchi, M. Fujii et al., Chem. Pharm. Bull., 49, 134 (2001), https://doi.org/10.1248/cpb.49.13410.1248/cpb.49.134 ↗
58. 58 B. Carlin and R. C. Moreton, Pharm. Technol., s36 2010, https://www.pharmtech.com/view/flexible-approaches-accommodate-excipient-variability-using-principles-qbd
59. 59 C. Sheehan, "USP Excipient Performance", ExcipientFest, Baltimore, Maryland, 2011
60. 60 USP37-NF32, Excipient Performance. U.S. Pharmacopeia, 2014. pp. 752-769.
61. 61 H. Wu, E. Heilweil, A. Hussain and M. Khan, Int. J. Pharm., 343, 148 (2007), https://doi.org/10.1016/j.ijpharm.2007.05.01410.1016/j.ijpharm.2007.05.014 ↗
62. 62 H. Wu, M. White and M. Khan, Org. Process Res. Dev., 19, 215 (2014), https://doi.org/10.1021/op500085m10.1021/op500085m ↗
63. 63 A. Guy, in "Handbook of Pharmaceutical Excipients", edited by R. C. Rowe, P. J. Sheskey and M. E. Quinn, Pharmaceutical Press (UK), 2009, pp. 129-133
64. 64 C. C. Sun, Int. J. Pharm., 346, 93 (2008), https://doi.org/10.1016/j.ijpharm.2007.06.01710.1016/j.ijpharm.2007.06.017 ↗
65. 65 T. Horio, M. Yasuda and S. Matsusaka, Int. J. Pharm., 473, 572 (2014), https://doi.org/10.1016/j.ijpharm.2014.07.04010.1016/j.ijpharm.2014.07.040 ↗
66. 66 K. Marshall and D. Sixsmith, Drug Dev. Commun., 1, 51 (1974), https://doi.org/10.3109/0363904740908816810.3109/03639047409088168 ↗
67. 67 T. Pesonen and P. Paronen, Drug. Dev. Ind. Pharm., 16, 591 (1990), https://doi.org/10.3109/0363904900910440510.3109/03639049009104405 ↗
68. 68 M. Dittgen, Manuf. Chem., 64, 17 (1993)10.1192/pb.17.1.64-c ↗
69. 69 K. A. Khan, P. Musikabhumma and J. P. Warr, Drug. Dev. Ind. Pharm., 7, 525 (1981), https://doi.org/10.3109/0363904810905772910.3109/03639048109057729 ↗
70. 70 F. Khan, N. Pilpel and S. Ingham, Powder Technol., 54, 161 (1988), https://doi.org/10.1016/0032-5910(88)80074-310.1016/0032-5910(88)80074-3 ↗
71. 71 D. R. Thio, Q. Aguilera, J. K. X. Yeoh, P. W. S. Heng and L. W. Chan, Int. J. Pharm., 643, 123245 (2023), https://doi.org/10.1016/j.ijpharm.2023.12324510.1016/j.ijpharm.2023.123245 ↗
72. 72 P. Luukkonen, T. Schaefer, L. Hellen, A. M. Juppo and J. Yliruusi, Int. J. Pharm., 188, 181 (1999), https://doi.org/10.1016/s0378-5173(99)00219-710.1016/S0378-5173(99)00219-7 ↗
73. 73 M. Rios, International Pharmaceutical Excipients Council, September, 2006, http://ipecamericas.org/newsletters/PT9-30-06e.pdf
74. 74 M. J. Tobyn, G. P. McCarthy, J. N. Staniforth and S. Edge, Int. J. Pharm., 169, 183 (1998), https://doi.org/10.1016/S0378-5173(98)00127-610.1016/S0378-5173(98)00127-6 ↗
75. 75 J. M. Siebert, R. K. Khankari, K. Rajendra, U. Kositprapa and P. S. Indiran, US 6368625 (2002)
76. 76 M. Bianchi and L. Capurso, Dig. Liv. Dis. 34, S129 (2002), https://doi.org/10.1016/s1590-8658(02)80180-310.1016/S1590-8658(02)80180-3 ↗
77. 77 G. Paturi, C. Butts, J. Monro, K. Nones, S. Martell et al., J. Agric. Food Chem., 58 6510 (2010), https://doi.org/10.1021/jf100296m10.1021/jf100296m ↗
78. 78 B. A. C. Carlin, in: "Pharmaceutical Dosage Forms: Tablets", 3rd ed., vol. 2, edited by L. A. Augsburger and S. W. Hoag, Informa Healthcare, 2008, pp. 173-216
79. 79 H. Zhao, L. Zhao, X. Lin and L. Shen, Carbohyd. Polym., 278, 118968 (2022), https://doi.org/10.1016/j.carbpol.2021.118968.10.1016/j.carbpol.2021.118968 ↗
80. 80 J. Conceicao, O. Adeoye, H. M. Cabral-Marques and J. M. Sousa Lobo, AAPS PharmSciTech, 19, 2710 (2018), https://doi.org/10.1208/s12249-018-1115-z10.1208/s12249-018-1115-z ↗
81. 81 S. Bozdag-Pehlivan, B. Subasi, I. Vural, N. Unlu and Y. Capan, Acta Pol. Pharm., 68, 423 (2011)
82. 82 S. S. Al-Nimry, S. M. Assaf, I. M. Jalal and N. M. Najib, Int. J. Pharm., 149, 115 (1997), https://doi.org/10.1016/S0378-5173(96)04857-010.1016/S0378-5173(96)04857-0 ↗
83. 83 J. T. Carstenses and R. C. Kothari, J. Pharm. Sci., 72, 1149 (1983), https://doi.org/10.1002/jps.260072101010.1002/jps.2600721010 ↗
84. 84 R. M. Franz and G. E. Peck, J. Pharm. Sci., 71, 1193 (1982), https://doi.org/10.1002/jps.260071110310.1002/jps.2600711103 ↗
85. 85 S. Okada, H. Nakahara and H. Isaka, Chem. Pharm. Bull., 35, 761 (1987), https://doi.org/10.1248/CPB.35.76110.1248/cpb.35.761 ↗
86. 86 Y. Wu, J. Levons, A. S. Narang, K. Raghavan and V. M. Rao, AAPS PharmSciTech, 12, 1248 (2011), https://doi.org/10.1208/s12249-011-9677-z10.1208/s12249-011-9677-z ↗
87. 87 N. Konar and C. Kim, J. Pharm. Sci., 86, 1339 (1997), https://doi.org/10.1021/js970267510.1021/js9702675 ↗
88. 88 M. A. Qtaitat, M. B. Zughul and A. A. Badwan, Drug. Dev. Ind. Pharm., 14, 415 (1988), https://doi.org/10.3109/0363904880915187410.3109/03639048809151874 ↗
89. 89 H. Matsumaru, VII Yakugaku Zasshi, 79, 198 (1959), https://doi.org/10.1248/yakushi1947.79.2_19810.1248/yakushi1947.79.2_198 ↗
90. 90 M. Nilsson and M. Stromme, J. Phys. Chem. B, 109, 5450 (2005), https://doi.org/10.1021/jp046991a10.1021/jp046991a ↗
91. 91 D. Markl and J. Axel Zeitler, Pharm. Res., 34, 890 (2017), https://doi.org/10.1007/s11095-017-2129-z10.1007/s11095-017-2129-z ↗
92. 92 D. A. Silva, G. K. Webster, N. Bou-Chacra and R. Lobenberg, Dissol. Technol., 25, 30 (2018), https://doi.org/10.14227/DT250318P3010.14227/DT250318P30 ↗
93. 93 P. M. Desai, C. V. Liew and P. W. S. Heng, J. Pharm. Sci., 105, 2545 (2016), https://doi.org/10.1016/j.xphs.2015.12.01910.1016/j.xphs.2015.12.019 ↗
94. 94 E. Lahdenpaa, M. Niskanen and J. Yliruusi, Eur. J. Pharm. Biopharm., 43, 315 (1997), https://doi.org/10.1016/S0939-6411(97)00053-210.1016/S0939-6411(97)00053-2 ↗
95. 95 S. C. Gad (Ed.), "Pharmaceutical Manufacturing Handbook: Production and Processes", John Wiley & Sons, 2008, pp. 351-367
96. 96 Y. X. Bi, H. Sunada, Y. Yonezawa and K. Danjo, Drug. Dev. Ind. Pharm., 25, 571 (1999), https://doi.org/10.1081/ddc-10010221110.1081/DDC-100102211 ↗
97. 97 C. F. Lerk, G. K. Bolhuis and A. H. de Boer, J. Pharm. Sci., 68, 205 (1979), https://doi.org/10.1002/jps.2600680222.10.1002/jps.2600680222 ↗
98. 98 H. Nogami, T. Nagai and H. Uchida, Chem. Pharm. Bull., 14, 152 (1966), https://doi.org/10.1248/cpb.14.15210.1248/cpb.14.152 ↗
99. 99 J. K. Spence, S. N. Bhattachar, J. A. Wesley, P. J. Martin and S. R. Babu, Pharm. Dev. Technol., 10, 451 (2005), https://doi.org/10.1080/1083745050029963610.1080/10837450500299636 ↗
100. 100 S. K. Battu, M. A. Repka, S. Majumdar and Y. M. Rao, Drug. Dev. Ind. Pharm., 33, 1225 (2007), https://doi.org/10.1080/0363904070137788810.1080/03639040701377888 ↗